CompaniesAblacon

Ablacon

defunct
About

Defunct Company

Areas of Focus

Categories

Bankrupt, Merged, Sold, Renamed or Otherwise Defunct
Clinical Trials (4)
View all

Total Trials

4

As Lead Sponsor

2

As Collaborator

2

Total Enrollment

520

By Phase

NA: 3

By Status

COMPLETED: 3ACTIVE_NOT_RECRUITING: 1
Clinical Trials Pipeline4 trials
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Phase 1/2
Phase 2/3
N/A
2018
2019
2020
2021
2022
2023
2024
2025
2026
2027
Today
NCT04473963
NCT05883631
Hover over trial bars to see details

Recent Trials

NCT05883631Collaborator
RESOLVE-AF: Clinical Evaluation of the Ablacath™ Mapping Catheter and Ablamap® System Utilizing Electrographic Flow (EGF) Mapping to Resolve Extra-PV Sources of Atrial Fibrillation and Guide Ablation Therapy.
NAActive, not recruiting
400 participants
Started: Oct 23, 2023 · Completed: Jan 31, 2026
NCT05481359Lead Sponsor
AF-FLOW Registry to Evaluate Electrographic Flow Mapping in Patients Undergoing Ablation for Atrial Fibrillation
N/ACompleted
25 participants
Started: Sep 12, 2022 · Completed: Nov 17, 2023
NCT06260670Lead Sponsor
FLOW EVAL-AF: FLOW Mapping Electrogram VALidation in Patients With Persistent Atrial Fibrillation
NACompleted
10 participants
Started: Sep 1, 2022 · Completed: Oct 28, 2022
NCT04473963Collaborator
FLOW-AF: A Study to Evaluate Electrographic Flow™ (EGF) Mapping Technology
NACompleted
85 participants
Started: Sep 27, 2019 · Completed: Sep 27, 2021
Funding History (2)
D
Dec 4, 2020
Filing
D
May 3, 2019
Filing